A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

Peer Review reports

Original Submission
14 Sep 2011	Submitted	Original manuscript
6 Nov 2011	Reviewed	Reviewer Report - Teresa Rolle
8 Nov 2011	Reviewed	Reviewer Report - Randy Craven
14 Nov 2011	Reviewed	Reviewer Report - Marcelo Hatanaka
31 Jan 2012	Author responded	Author comments - David Eveleth
Resubmission - Version 2
31 Jan 2012	Submitted	Manuscript version 2
12 Feb 2012	Reviewed	Reviewer Report - Teresa Rolle
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
18 May 2012	Editorially accepted
18 May 2012	Article published	10.1186/1471-2415-12-9

Back to article page